MEET US AT CPHI NORTH AMERICA
|Dynorphins||Prodynorphin (PDYN)||Dynorphin A|
As outlined in Table 2 the endogenous opioid peptides exhibit different affinity and selectivity for the various opioid receptor subtypes.
Adapted from J.McDonald and D.Lambert, Opioid receptors. BJA Education 15, 219-224 (2014)
Opioid Receptor Signaling
All four opioid receptors couple to the inhibitory G proteins (Gαi and Gαo). They convey extracellular signals within the cells by activating the heterotrimeric G proteins, which interact with the cytoplasmic domains of the receptors. Upon activation, the Gα and Gβγ subunits dissociate from one another, allowing them to act upon their downstream effectors and thereby initiate a variety of intracellular signaling responses. These include suppression of adenylate cyclase activity by Gα subunits, thereby reducing cyclic AMP production, and inhibition of voltage-gated calcium channels (VGCC) as well as activation of G protein-gated inwardly rectifying potassium (GIRK) channels by Gβγ subunits.
Receptor activation also results in receptor phosphorylation by G protein-coupled receptor kinases, which increases its affinity for β-arrestin molecules. β-Arrestin molecules are involved in the regulation of G protein signaling through receptor desensitization and internalization. They also act as scaffold bringing together other proteins to activate separate signaling pathways including the mitogen-activated protein kinase (MAPK) cascade. Biased opioid receptor ligands stabilize receptor conformations preferentially activating either the G protein or the β-arrestin pathway (Figure 1). The discovery of this type of ligands has opened a new area of drug research, aiming for example, at the design of drugs with less side effects.
There is also evidence that opioid receptors can form heterodimers composed of different opioid receptors, which offers the potential to develop bivalent ligands with unique pharmacological properties.
Figure 1 Biased Ligands Preferentially Signal Through The G Protein or The β-Arrestin Pathway
Adapted from S.Spangler and M.R.Bruchas, Tuning biased GPCR signaling for physiological gain. Cell 171, 989-991 (2017)
Exorphins, also known as exogenous opioid peptides, are short food-derived peptides. They can arise during digestion through the enzymatic cleavage of proteins by enzymes such as pepsin, trypsin and chymotrypsin. The most common food sources for these bioactive peptides are milk or dairy products, soybean, cereals, and green vegetables such as spinach. Examples of exorphins are given in Table 3. The physiological significance of these peptides remains controversial. They have been implicated in autism and schizophrenia and might be involved in emotional behavior and memory processes by influencing hormonal or neurotransmitter systems via opioid receptors.
|Gluten Exorphin A5||GYYPT||Gluten||DOP|
|Soymorphin-5||YPFVV||Soybean β-conglycinin β-subunit||MOP|
|β-Casomorphin-5||YPFPG||β-Casein from bovine milk||MOP|
|Rubiscolin-5||YPLDL||D-Ribulose-1,5-bisphosphate carboxylase/oxygenase from spinach leaves||DOP|
|Rubiscolin-6||YPLDLF||D-Ribulose-1,5-bisphosphate carboxylase/oxygenase from spinach leaves||DOP|
The opioid system is involved in addictive and emotional behaviors and the regulation of pain and stress responses. It mainly represents a therapeutic target for the management of pain but also offers starting points for the treatment of emotional disorders and addictive diseases. Bachem offers a range of opioid research related products in order to support advancements in these research areas.
G.Corder, D.C.Castro, M.R.Bruchas, G.Scherrer, Endogenous and exogenous opioids in pain. Annual Review of Neuroscience 2018, 41, 453-473.
A.Stefanucci, A.Mollica, G.Macedonio, G.Zengin, A.A.Ahmed, E.Novellino, Exogenous opioid peptides derived from food proteins and their possible uses as dietary supplements: A critical review. Food Reviews International 2018, 34, 70-86.
R.J.Valentino, N.D.Volkow, Untangling the complexity of opioid receptor function. Neuropsychopharmacology 2018, 43, 2514-2520.
J.M.Wenzel, J.F.Cheer, Endocannabinoid regulation of reward and reinforcement through interaction with dopamine and endogenous opioid signaling. Neuropsychopharmacology 2018, 43, 103-115.
R.I.Anderson, H.C.Becker, Role of the dynorphin/kappa opioid receptor system in the motivational effects of ethanol. Alcoholism, Clinical and Experimental Research 2017, 41, 1402-1418.
K.M.Olson, W.Lei, A.Keresztes, J LaVigne, J.M Streicher, Novel molecular strategies and targets for opioid drug discovery for the treatment of chronic pain. Yale Journal of Biology and Medicine 2017, 90, 97-110.
S.Spangler, M.R.Bruchas, Tuning biased GPCR signaling for physiological gain. Cell 2017, 171, 989-991.
J.S.Smith, S.Rajagopal, The beta-arrestins: Multifunctional regulators of G protein-coupled receptors. The Journal of Biological Chemistry 2016, 291, 8969-8977.
L.Toll, M.R.Bruchas, G.Calo, B.M.Cox, N.T.Zaveri, Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacological reviews 2016, 68, 419-457.
J.McDonald, D.Lambert, Opioid receptors. BJA Education 2014, 15, 219-224.
E.E.Benarroch, Endogenous opioid systems. Neurology 2012, 79, 807.
D.S.Sauriyal, A.S.Jaggi, N.Singh, Extending pharmacological spectrum of opioids beyond analgesia: multifunctional aspects in different pathophysiological states. Neuropeptides 2011, 45, 175-188.
B.A.Gosnell, A.S.Levine, Reward systems and food intake: role of opioids. International Journal of Obesity 2009, 33, S54.
B.L.Kieffer, Opioid peptides and receptors. In: Squire LR (ed). Encyclopedia of Neuroscience. Academic Press: Oxford, 2009, 235-240.
A.Koneru, S.Satyanarayana, S.Rizwan, Endogenous opioids: Their physiological role and receptors. Global Journal of Pharmacology 2009, 3, 149-153.
J.C.Froehlich, Opioid peptides. Alcohol Health & Research World 1997, 21, 132-136.
Opioid peptides are known to play a role in analgesia, feeding, memory, motivation, immune responses and a variety of other functions. Opioid receptors serve as important drug targets and opioid peptide analogs are of interest for the treatment of pain and other conditions such as mood disorders and substance abuse (1). For example, peptide-based analgesics are being explored in the search for safer alternatives to existing opioid drugs because they may produce less tolerance, respiratory suppression, and addiction. There are several promising opioid peptides in clinical development for various indications as shown in Table 4.
|Product Name||Generic Name||Indication||Highest Phase||Companies|
|Korsuva™||difelikefalin||Uremic Pruritus, Post-Operative Pain, Pain, Pruritis, Osteoarthritis Pain, Chronic Liver Disease||III||Cara Therapeutics|
|REC-0438||--||Overactive bladder||II||Recordati SpA|
|MENK||Metenkefalin||Ovarian Cancer, Head and Neck Cancer, Human Immunodeficiency Virus Infections, Pancreatic Cancer||II||Cytocom Inc|
|Enkorten®||Metenkefalin + tridecactide||Relapsing Remitting Multiple Sclerosis||II||Farmacija d.o.o. Tuzla|
|ZYKR-1||--||Visceral Pain, Post-Operative Pain||IND/CTA Filed||Cadila Healthcare Ltd|
Phase III Candidates
Cara Therapeutics is developing KorsuvaTM, a κ-opioid receptor agonist, for the treatment of post-operative pain, uremic pruritus, chronic and acute pain, and chronic liver disease. In January 2019, Cara Therapeutics completed enrollment of the KALM-1 Phase III trial of Korsuva in hemodialysis patients with pruritus (2).
Phase II Candidates
REC-0438 is under development at Recordati SpA for the treatment of overactive bladder in pediatric spina bifida patients with spinal lesions and neurogenic detrusor overactivity. This product candidate is a nociceptin analog that acts by agonizing the Opioid Receptor-Like 1 (OPRL1) receptor. In 2018, Recordati registered a Phase II trial to study the effects of two different doses of REC-0438 in patients with neurogenic detrusor overactivity (NDO) due to spinal cord injury (2).
Cytocom is developing MENK, a potent opioid peptide, which influences DNA synthesis and cell growth. Research studies have shown that MENK can inhibit cancerous cell growth and boost the immune system (3). The candidate is in Phase II development for pancreatic cancer, ovarian cancer, hepatocellular carcinoma, head and neck cancer, and Human Immunodeficiency Virus (HIV) Infections (AIDS). MENK treatment is administered by first isolating a patient’s lymphocytes and incubating them with IRT-101. Following incubation, the lymphocytes are re-infused back into the patient to kill tumor cells (2).
Enkorten®, a combination of metenkefalin and tridecactide, is under development at Farmacija d.o.o. Tuzla for the treatment of relapsing remitting multiple sclerosis (RRMS). Metenkefalin targets the δ-opioid receptor and tridecactide targets the melanocortin receptor. In 2017, a Phase IIIb trial was registered which will evaluate the efficacy, safety and tolerability of Enkorten in patients with RRMS (2).
Phase I Candidates
Cadila Healthcare is developing ZYKR-1 for the treatment of visceral pain and post-operative pain. ZYKR-1 acts as a κ-opioid receptor agonist. In 2018, the company registered a Phase I study of ZYKR-1 to evaluate the safety, pharmacokinetics and pharmacodynamics in healthy volunteers. The trial will take place in India (2).
Research and development surrounding opioid peptides has expanded from emphasis on pain regulation to include other indications such as cancer and RRMS. For researchers and organizations working on the research and development of opioid peptides, Bachem offers a wide selection of opioid peptides, a comprehensive custom peptide synthesis service, and the production of New Chemical Entities.
(1) J.V.Aldrich, J.P. McLaughlin, Opioid Peptides: Potential for Drug Development. Drug Discov. Today Technol. 9, e23-e31 (2019)
(2) GlobalData (2019)
(3) MENK. Cytocom (2019)
What is your official job title at Bachem?
I am Group Leader Relationship Marketing.
How long have you been with Bachem? Where did you work before Bachem?
I started my job at Bachem October 1, 2018. Before joining Bachem I worked as a Laboratory Head and as Customer Project Leader of an analytical service provider.
What is your academic background?
I’m biologist with background in immunology and lung physiology. I obtained a Ph.D. at University of Bern in the field of nanoparticle research.
What do you like most about your job?
Bachem gives me the opportunity to work in a motivated and engaged team. It is also fun working cross-functional within the matrix organization. I especially like the variety of tasks.
What is your business motto?
Be reliable, treat everybody with respect and take responsibility for your tasks – always having the customer in focus.
What do you like to do outside of work?
In the winter season I like to go skiing in the mountains, in summer season I love to go swimming in the river Rhine. In general, I enjoy cooking, traveling, going to the theater and spending time with family and friends. Apart from that, I love to take care for a small vineyard together with some friends. It is hard work but it is also fun as in the end you get a perfect result.
Thank you very much Nadine.
Interesting news about peptides in basic research and pharmaceutical development:
Peptide derived from fungi kills TB bacteria-Lund University
USC dental researchers developing special film that could revolutionize the way peri-implantitis treated-University of Southern California
Novel peptide-based immunotherapy holds promise for peanut allergy-Pulmonary Advisor